Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

Healthcare Biotechnology
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

StageZero Life Sciences Ltd
Bullboard Posts
User Avatar Image
(252)
•••
Comment by KPOIndustrieson May 08, 2020 7:05am
167 Views
Post# 31001679

RE:RE:RE:Time to get this board working.

RE:RE:RE:Time to get this board working.

THIS is what I'm talking about!! Nails is the man! Beckham Coulture says that they will have their test released in May. Well, it's May... this may actually be that tangible WHO that Nails is talking about.

 

Nailbiter1 wrote: The big news might not be the "who", rather the "how many". I don't think public knowledge of Beckman Coulture will be a knock out. Material info like how many tests will be delivered and so on. Still, anything is everything in this covid environment.

SAGDollar wrote: Hey Nail!  Did IR tell you that today? If so I'm wondering if that means we are getting a NR before the bell tomorrow. Once again thanks for your insight!!




Nailbiter1 wrote:

Word is out from IR that our partner for the Quantitative test is a partner we are already doing business with.

Beckman Coulter is our PHI prostate cancer partner. 
Remember Gary the Prostate?

They are going to offer their top notch antibody test to us and
I am going so far out of my mind that I'm right back in it again.

Pull out those shovels and start digging.

Here's a good start.

https://www.beckmancoulter.com/en/blog/diagnostics/fighting-covid-19-impact-with-serology-testing


 




Bullboard Posts
Dealroom for high-potential pre-IPO opportunities